Cargando…

Transcriptomic Profiling of Tumor-Infiltrating CD4(+)TIM-3(+) T Cells Reveals Their Suppressive, Exhausted, and Metastatic Characteristics in Colorectal Cancer Patients

T cell immunoglobulin mucin-3 (TIM-3) is an immune checkpoint identified as one of the key players in regulating T-cell responses. Studies have shown that TIM-3 is upregulated in the tumor microenvironment (TME). However, the precise role of TIM-3 in colorectal cancer (CRC) TME is yet to be elucidat...

Descripción completa

Detalles Bibliográficos
Autores principales: Sasidharan Nair, Varun, M Toor, Salman, Z Taha, Rowaida, Ahmed, Ayman A, Kurer, Mohamed A, Murshed, Khaled, Soofi, Madiha E, Ouararhni, Khalid, M. Alajez, Nehad, Abu Nada, Mohamed, Elkord, Eyad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7157206/
https://www.ncbi.nlm.nih.gov/pubmed/32041340
http://dx.doi.org/10.3390/vaccines8010071
Descripción
Sumario:T cell immunoglobulin mucin-3 (TIM-3) is an immune checkpoint identified as one of the key players in regulating T-cell responses. Studies have shown that TIM-3 is upregulated in the tumor microenvironment (TME). However, the precise role of TIM-3 in colorectal cancer (CRC) TME is yet to be elucidated. We performed phenotypic and molecular characterization of TIM-3(+) T cells in the TME and circulation of CRC patients by analyzing tumor tissues (TT, TILs), normal tissues (NT, NILs), and peripheral blood mononuclear cells (PBMC). TIM-3 was upregulated on both CD4(+) and CD3(+)CD4(−) (CD8(+)) TILs. CD4(+)TIM-3(+) TILs expressed higher levels of T regulatory cell (Tregs)-signature genes, including FoxP3 and Helios, compared with their TIM-3(−) counterparts. Transcriptomic and ingenuity pathway analyses showed that TIM-3 potentially activates inflammatory and tumor metastatic pathways. Moreover, NF-κB-mediated transcription factors were upregulated in CD4(+)TIM-3(+) TILs, which could favor proliferation/invasion and induce inflammatory and T-cell exhaustion pathways. In addition, we found that CD4(+)TIM-3(+) TILs potentially support tumor invasion and metastasis, compared with conventional CD4(+)CD25(+) Tregs in the CRC TME. However, functional studies are warranted to support these findings. In conclusion, this study discloses some of the functional pathways of TIM-3(+) TILs, which could improve their targeting in more specific therapeutic approaches in CRC patients.